Rethinking Clinical Development and Patient Engagement — Where the Real Transformation Is Happening

The life sciences industry has always worked at the edge of science, regulation, and innovation. But over the past few years, what used to be future-state goals—decentralized trials, remote monitoring, patient-first design—are quickly becoming the standard.

It’s not just about adopting technology. It’s about rebuilding how clinical development and patient engagement happen—so trials run faster, data becomes more useful, and patients are no longer just participants but partners.

The ISG Global 2024 Life Sciences Digital Services Report, led by Rohan Sinha and co-authored by Sneha Jayanth—both analysts at ISG—highlights this shift. It also confirms that Hexaware is helping lead it—named a Leader in both Clinical Development and Patient Engagement quadrants for our deep domain experience, automation-first approach, and ability to scale personalized, digital programs across the life sciences value chain.

Here’s a clear look at where the industry is going—and how we’re helping clients get there faster.

Trials Are Moving Closer to Patients—and Further from Legacy Models

Decentralized trials are no longer a niche concept. They’re now a mainstream strategy.

According to ISG, pharmaceutical companies, CROs, tech providers, and even regulators are aligning around a decentralized-first mindset. That means:

• Fewer site visits
• Remote monitoring through wearables and apps
• Digital consent and enrollment
• Real-time data capture and analysis

The benefits are obvious—greater access to diverse populations, improved patient convenience, better adherence, and more efficient data flow. But the implementation challenges are real too. Integrating decentralized data into traditional trial infrastructure takes planning. And getting digital tools to work across geographies, devices, and patient populations requires more than just good code—it demands empathy in design and rigor in execution.

ISG’s report puts it bluntly: success in decentralized clinical development will hinge on how well tech partners understand the operational, regulatory, and human sides of trials.

Patient Engagement Isn’t an Add-On—It’s the Center of the Model

The ISG Global 2024 Life Sciences Digital Services Report highlights a shift in how life sciences companies are approaching patient engagement strategies. It’s no longer about pushing information to patients—it’s about bringing them into the process from the start.

That means:

• Designing platforms that patients can navigate on their own terms
• Using wearables and connected devices to collect data passively
• Offering omnichannel support (text, video, mobile apps) to meet people where they are
• Giving patients a say in trial design, delivery, and ongoing communication

In the report, ISG lead analyst Rohan Sinha calls out the move from physician-centered models to patient-first ecosystems. Companies are realizing that engagement can’t happen if the tools are clunky or the workflows are built for providers instead of people.

Where the Leaders Stand—and Why Hexaware Is One of Them

Only a select few providers were named Leaders by ISG in both Clinical Development and Patient Engagement. Here’s a short, alphabetically listed lineup of the top global SIs that made the cut:

Leaders – Clinical Development (Global)

 Leaders – Patient Engagement (Global)

What ISG Says About Hexaware

In Patient Engagement, ISG highlights our:

• Tailored suite of accelerators for preconfigured service hubs, eConsent, and personalized outreach
• Integration of IoT devices (Apple Watch, Alexa, Fitbit, and medical-grade monitors) for seamless, real-time data collection
• Advanced data management systems built on Salesforce Cloud
• Strategic partnerships with MuleSoft, Apigee, Boomi, and Microsoft FHIR APIs for secure and HIPAA-compliant data exchange
• Ability to plug into EDC and CRM systems using tools like SnapLogic for smoother implementation

In Clinical Development, the report emphasizes:

• Our automation-first framework for clinical development transformation
• Accelerators for protocol design, feasibility analysis, site selection, and patient recruitment
• Ability to digitize lab and diagnostic data from wearables, apps, and home devices
• GenAI-driven analysis for adverse events, medical review, and site monitoring
• Clinical data lakes for multi-format ingestion and real-time analytics
• Robust partnerships across CROs, cloud vendors, and regulatory platforms

In short, ISG sees Hexaware not just as a delivery partner, but as a domain-aware enabler of modern clinical operations.

5 Key Trends Shaping Clinical and Patient Programs (And What to Do About Them)

Let’s break down the core trends from both reports and how we help life sciences companies respond—practically.

1. Decentralized Trials Are the New Baseline

• What’s happening: Trials are being redesigned around remote interaction—from recruitment to monitoring. Wearables, ePROs, and home visits are part of the core protocol now.
• Hexaware’s approach: We help sponsors integrate decentralized trial platforms into their existing ecosystem—without disrupting compliance, data models, or trial timelines. Our clinical-grade IoT connectors and prebuilt APIs make it easier to ingest and act on patient-generated data in real time.

2. Patient-Centric Design Must Go Beyond the Buzzword

• What’s happening: Engagement is becoming a business and clinical metric—not just a marketing one. But many tools are still built for HCPs, not people.
• Hexaware’s approach: We design with accessibility and personalization in mind. Our accelerators support multi-language interfaces, context-aware nudges, eConsent, and patient education—all pre-integrated with Salesforce or Veeva platforms.

3. AR and VR Are Entering Clinical Operations

• What’s happening: Sponsors are using virtual tools to educate patients, simulate visits, and even conduct training for trial staff.
• Hexaware’s approach: We develop AR/VR modules for trial onboarding, protocol walkthroughs, and virtual site visits—helping both patients and investigators engage more clearly and confidently.

4. AI and GenAI Are Rewriting the Rules of Trial Analysis

• What’s happening: AI is moving from backend data mining to active front-end decision-making—in feasibility studies, risk detection, adverse event analysis, and beyond.
• Hexaware’s approach: Our GenAI models are trained on clinical taxonomies and patient data sets to automate document processing, surface trends, and accelerate site monitoring and medical review.

5. Security and Compliance Can’t Be an Afterthought

• What’s happening: As more patient data flows through non-traditional channels, the risk exposure grows. Regulators are watching.
• Hexaware’s approach: All our integrations meet HIPAA and GDPR requirements. Our API ecosystem ensures secure, traceable data movement, and we run compliance scans across every patient engagement module we deploy.

What to Look for in a Strategic Partner—Not Just a Vendor

Organizations reimagining their clinical trials or digital patient engagement platforms need more than just a service provider. They need a strategic partner who:

• Navigates complex regulatory landscapes across global markets
• Delivers at speed without adding operational overhead
• Offers prebuilt accelerators without being limited by them
• Enables seamless integration—without forcing a replatform
• Connects patient experience with trial performance
• Treats decentralization and engagement as integrated, not isolated, initiatives

That’s where Hexaware distinguishes itself. With deep domain knowledge and an AI-first approach, Hexaware helps life sciences firms redesign how they conduct trials, engage patients, and harness data, without waiting on a massive transformation program to get started.

The Future of Life Sciences Is Patient-First and Digitally Connected

The ISG reports make it clear; leaders in clinical development and patient engagement aren’t just adopting digital tools. They’re embedding them into the core of how they operate.

That shift requires new thinking, new workflows, and the right partners to make it real. Hexaware is already helping global life sciences firms run faster trials, deliver better patient experiences, and modernize without disruption.

If you’re ready to connect the dots between digital, data, and patient outcomes—let’s talk.